How does tirzepatide work?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics two naturally occurring gut hormones released after meals, activating both receptor pathways simultaneously.
GLP-1 receptor activation slows gastric emptying, increases satiety signaling in the hypothalamus, and reduces appetite. GIP receptor activation appears to work synergistically with GLP-1 pathways in ways that are still being characterized. The dual mechanism is why tirzepatide produced larger weight reductions in trials than GLP-1-only compounds in direct comparisons.
Tirzepatide is an FDA-approved prescription drug (indicated for blood sugar management and weight management under separate brand names). Compounded tirzepatide is available through licensed 503Apharmacies with a clinician’s prescription via a separate regulatory pathway. Compounded formulations are not FDA-approved. No hidden overseas supply chain.
How does retatrutide work?
Retatrutide is an investigational triple receptor agonist. It targets the same GIP and GLP-1 receptors as tirzepatide, and adds a third target: the glucagon receptor. This triple mechanism is the key pharmacological difference between the two compounds.
Glucagon receptor activation increases energy expenditure and promotes fat oxidation — effects that GLP-1 and GIP agonism alone do not achieve. The theory is that adding glucagon receptor activity on top of the appetite-suppressing effects of GIP and GLP-1 agonism could produce a more favorable energy balance with greater fat loss.
The Phase II trial of retatrutide published in 2023 reported mean weight reductions of approximately 17–24% depending on dose at 48 weeks, with the highest dose arm achieving outcomes at the upper end of that range. These numbers generated significant attention in the field. But Phase II results involve smaller populations, shorter timelines, and less rigorous conditions than Phase III trials. Phase III is where compounds often fail, or succeed more modestly than early data suggested.
The real gap isn’t a third receptor — it’s that one of these compounds has years of Phase III evidence and a legal pathway, and the other has neither yet.
What does the evidence gap between tirzepatide and retatrutide mean for patients?
Comparing tirzepatide and retatrutide directly is complicated by the asymmetry of evidence. Tirzepatide has completed Phase III trials in multiple populations, including the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity. These are large, well-powered, randomized controlled trials. The safety and efficacy profile is characterized in detail.
Retatrutide has one published Phase II trial. That trial enrolled fewer than 500participants. It did not include head-to-head comparison with tirzepatide. Side effect profiles at scale, drug interactions, contraindication data, and long-term outcomes are all undetermined. This does not mean retatrutide will fail to demonstrate similar or superior efficacy in Phase III — it means we do not know yet.
Patients who read headlines announcing that retatrutide “outperformed” tirzepatide should understand that those comparisons are across different trials with different populations, study designs, and endpoints. They are not head-to-head findings.
Can you get tirzepatide or retatrutide right now?
Tirzepatide is available today through clinician-supervised telehealth in states where the prescribing clinician is licensed. Compounded tirzepatide is prepared by licensed 503A pharmacies in the USA under the regulatory pathway for patient-specific compounding.
Retatrutide is not available. It has not received FDA approval. It cannot be legally compounded by licensed compounding pharmacies. Any vendor claiming to offer “retatrutide” is operating outside legal compounding channels, with all the quality, purity, sterility, and dosing risks that implies. PepScribe does not offer retatrutide and advises strongly against obtaining any peptide or research compound from unregulated sources.
Should you wait for retatrutide before starting tirzepatide?
This is a genuine clinical question worth thinking through. The answer depends on three factors:
- Your current weight-related health risks and how much delay you can afford.
- How much incremental benefit retatrutide might realistically offer over tirzepatide.
- How long you are willing to wait for a drug that may or may not reach approval on the expected timeline.
The obesity medicine community generally does not recommend deferring available, evidence-based treatment to wait for an unapproved compound. The cardiometabolic consequences of obesity are cumulative; delay has real costs. If retatrutide is approved and offers superior outcomes for your situation, switching is an option that a clinician can evaluate at that time.
For most patients considering tirzepatide vs retatrutide, the practical answer is: tirzepatide is available now with a strong evidence base and a clear clinician pathway. Retatrutide is scientifically interesting and may prove superior in certain populations, but it is not a decision that can be acted on yet.
How does PepScribe approach tirzepatide?
PepScribe offers clinician-supervised compounded tirzepatide as a Tier 1 peptide therapy. A licensed clinician reviews your intake, confirms eligibility, and prescribes if appropriate. The medication is formulated in licensed 503A pharmacies in the USA. Compounded tirzepatide is not FDA-approved; it is dispensed through the 503A compounding pathway, which is distinct from branded prescription products.
The clinician assessment also considers whether semaglutide or tirzepatide is the better fit for your situation. You are not committed to a specific molecule before the clinician reviews your case.